Table 3.
Bivariate relationship between patients’ characteristics (n = 131) and direct oral anticoagulant levels at first measurement
| Variable | Levels below expected range (n = 19 [14.5%]) | Levels within range (n = 91 [69.5%]) | Levels above expected range (n = 21 [16.0%]) | p valuea |
|---|---|---|---|---|
| Female | 5 (26.3) | 48 (52.7) | 13 (61.9) | 0.06 |
| Age (years) | 80 (72–87) | 80 (70–84) | 79 (74–86) | 0.90 |
| Weight (kg) | 72.8 (62.3–90.3) | 68.9 (59.5–81.3) | 65 (55.5–76.4) | 0.39 |
| Creatinine (mmol/L) | 90 (66–103.5) | 86.5 (70–123.8) | 110 (86.8–169.8) | 0.1 |
| DOAC doseb | 0.96 | |||
| Standard dose | 6 (31.6) | 34 (37.4) | 8 (38.1) | |
| Reduced dose | 13 (68.4) | 57 (62.6) | 13 (61.9) | |
| Patients treated with EI-ASM, n = 24 | 9 (37.5) | 15 (62.5) | 0 (0.0) | 0.0004 |
| Patients without EI-ASM, n = 107 | 10 (9.3) | 76 (71.0) | 21 (19.6) |
Data are presented as n (%) or median (interquartile range)
DOAC direct oral anticoagulant, EI-ASM enzyme-inducing antiseizure medication
aCalculated using Chi-squared and Fisher’s exact test for categorical measures, and Kruskal–Wallis test for continuous measures
bDosing as per guidelines